Latest Cancer immunotherapy Stories
LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012.
Robust Clinical Development Programs Across Sellas' Portfolio of Drugs and Biologics ZUG, Switzerland and NEW YORK, Oct.
TUBINGEN, Germany, October 14, 2014 /PRNewswire/ -- Regulatory authority approves clinical trial for Glioma Actively Personalized
LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy.
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS
-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept.
The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.
Unique Multivalent WT1 Vaccine to be developed across hematological malignancies and solid tumors NEW YORK, Sept.
Initial Closing is for $10 Million FREDERICK, Md., Aug.
- The parings of haberdine; also, any kind of fragments.